COX-2 selective inhibitors and bone

被引：25
|
作者：
Goodman, SB
Ma, T
Genovese, M
Smith, RL
机构：
[1] Stanford Univ, Ctr Med, Dept Orthopaed Surg, Stanford, CA 94305 USA
[2] Stanford Univ, Ctr Med, Div Rheumatol & Immunol, Stanford, CA 94305 USA
来源：
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY | 2003年 / 16卷 / 03期
关键词：
non-steroidal anti-inflammatory drugs; cyclooxygenase inhibitors; bone; animal studies;
D O I：
10.1177/039463200301600303
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely prescribed medications for relief of pain and inflammation. Recent animal studies using models of fracture healing and bone ingrowth suggest that NSAIDs (both non-selective NSAIDs and selective COX-2 inhibitors) adversely affect these bone-related processes. The dose and time-relationships of these medications and their resulting effects on bone have not yet been fully elucidated. Furthermore, whether COX-2 inhibitors and non-selective NSAIDs lead to clinically relevant adverse effects on bone healing in humans is unknown.
引用
收藏
页码：201 / 205
页数：5
相关论文
共 50 条
  • [1] Nephrotoxicity of selective COX-2 inhibitors
    Woywodt, A
    Schwarz, A
    Mengel, M
    Haller, H
    Zeidler, H
    Köhler, L
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (09) : 2133 - 2135
  • [2] COX-2 Selective Inhibitors in the Treatment of Osteoarthritis
    Laine, Loren
    White, William B.
    Rostom, Alaa
    Hochberg, Marc
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2008, 38 (03) : 165 - 187
  • [3] Risk of hyperkalemia associated with selective COX-2 inhibitors
    Aljadhey, Hisham
    Tu, Wanzhu
    Hansen, Richard A.
    Blalock, Susan
    Brater, Craig
    Murray, Michael D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 (11) : 1194 - 1198
  • [4] The role of COX-2 in acute pain and the use of selective COX-2 inhibitors for acute pain relief
    Lee, Y
    Rodriguez, C
    Dionne, RA
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (14) : 1737 - 1755
  • [5] Adverse effects of COX-2 inhibitors
    Sharma, Jagdish N.
    Jawad, Najeeba M.
    THESCIENTIFICWORLDJOURNAL, 2005, 5 : 629 - 645
  • [6] Efficacy of the newest COX-2 selective inhibitors in rheumatic disease
    Baraf, Herbert S. B.
    CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (22) : 2228 - 2236
  • [7] THE DEVELOPMENT OF COX-1 AND COX-2 INHIBITORS: A REVIEW
    Vishwakarma, Rahul Kumar
    Negi, D. S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2020, 11 (08): : 3544 - 3555
  • [8] COX-2 inhibitors: A review
    Houston, AM
    Teach, SJ
    PEDIATRIC EMERGENCY CARE, 2004, 20 (06) : 396 - 399
  • [9] Selective cyclooxygenase-2 (COX-2) inhibitors and breast cancer risk
    Ashok, Varun
    Dash, Chiranjeev
    Rohan, Thomas E.
    Sprafka, J. Michael
    Terry, Paul D.
    BREAST, 2011, 20 (01) : 66 - 70
  • [10] Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships
    Zarghi, Afshin
    Arfaei, Sara
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2011, 10 (04): : 655 - 683
12345